NextCure, Inc.

NXTC · United States

Share price · NXTC

$6.88+0.23 (+3.53%) 3M

close as of 2026-11-18 · 24h delayed · vol 21K (0.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NXTC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026+17.6%
  2. 14 Jul 2026+201.8%
  3. 1 Jul 2026+21.9%
  4. 9 Jun 2026-16.5%
  5. 1 Jun 2026-45.5%
  6. 27 May 2026-13.5%
  7. 22 May 2026-23.2%
  8. 6 May 2026+15.0%
  9. 24 Apr 2026-15.2%
  10. 20 Apr 2026+13.3%

Share of unusual movement by asset

For each asset, the share of NXTC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
SIM0505
events and moves
6shown from 8 days
LNCB74
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—64%
Sessions with no dated event—33%

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 1/2
Collagen (LAIR-1 ligands)Protein / enzyme therapeutic
Colorectal Cancer
Phase 1
B7-H4Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1
Cadherin-6 (CDH6)Antibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$4.5M$8.7M$6.8M-$12M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$7.4M$15M+ $4.8M short-term inv.$15M-$9.7M operating cash flowreport ↗
2026-Q1—$6.8M$15M+ $15M short-term inv.$9.8M-$13M operating cash flowreport ↗
2025-Q3—$6.1M$7.3M+ $22M short-term inv.$8.6M-$6.3M operating cash flowreport ↗
2025-Q2—$24M$4.9M+ $30M short-term inv.$27M-$23M operating cash flowreport ↗
2025-Q1—$7.9M$22M+ $34M short-term inv.$11M-$13M operating cash flowreport ↗
2024-Q3—$8.8M$28M+ $48M short-term inv.$12M-$11M operating cash flowreport ↗
2024-Q2—$12M$21M+ $66M short-term inv.$15M-$9.8M operating cash flowreport ↗
2024-Q1—$11M$18M+ $78M short-term inv.$17M-$13M operating cash flowreport ↗
2023-Q3—$11M$20M+ $99M short-term inv.$14M-$13M operating cash flowreport ↗
2023-Q2—$13M$22M+ $109M short-term inv.$18M-$15M operating cash flowreport ↗
2023-Q1—$12M$30M+ $116M short-term inv.$16M-$15M operating cash flowreport ↗
2022-Q3—$14M$31M+ $138M short-term inv.$19M-$15M operating cash flowreport ↗
2022-Q2—$13M$28M+ $157M short-term inv.$18M-$14M operating cash flowreport ↗
2022-Q1—$15M$11M+ $191M short-term inv.$21M-$15M operating cash flowreport ↗
2021-Q3—$14M$37M$18M-$13M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$45M$26M+ $16M short-term inv.$14M-$50M operating cash flowreport ↗

NextCure did not disclose revenue for fiscal year 2025. R&D expense was $44.92M, up 8.3% YoY, and cash, cash equivalents, and marketable securities totaled $41.8M at year-end 2025, down $26.8M from $68.6M at the end of 2024. The company reported a net loss of $55.84M.

Management guided that current financial resources are expected to fund operations and capital expenditures into the first half of 2027 through proof-of-concept for SIM0505. SIM0505 Phase 1 dose escalation data and initiation of a Phase 1 dose optimization study in ovarian cancer are both anticipated in Q2 2026, with an LNCB74 Phase 1 dose escalation trial update planned for the second half of 2026. The company also noted the acquisition of SIM0505 rights and a November 2025 $21.5M private placement.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$41M$28M+ $41M short-term inv.$14M-$41M operating cash flowreport ↗
2023-FY—$48M$13M+ $95M short-term inv.$16M-$53M operating cash flowreport ↗
2022-FY—$54M$27M+ $133M short-term inv.$19M-$54M operating cash flowreport ↗
2021-FY—$50M$12M+ $207M short-term inv.$17M-$57M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 19 purchases ($1.9M), 1 sale ($185K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-11ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% ownerOpen-market purchase12,333$5.10$63KForm 4
2026-11-06ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% ownerOpen-market purchase3,662$5.10$19KForm 4
2026-11-05ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% ownerOpen-market purchase1,024$5.10$5KForm 4
2026-10-27ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% ownerOpen-market purchase3,553$5.10$18KForm 4
2026-10-26ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% ownerOpen-market purchase1,672$5.03$8KForm 4
2026-10-23ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% ownerOpen-market purchase5,626$4.83$27KForm 4
2026-08-10Simcere Zaiming, Inc.; Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.; Simcere Zaiming Pharmaceutical Co., Ltd.; Simcere Pharmaceutical Group Ltd; Ren Jinsheng; Tang Renhong · Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% OwnerOpen-market sale30,000$6.16$185KForm 4
2026-07-31ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% ownerOpen-market purchase3,300$4.98$16KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 26 reporting institutions held 2.2M shares ($22.8M, 47.4% of shares outstanding).

#InstitutionSharesValue
1Squadron Capital Management LLC265,000$2.8M
2Affinity Asset Advisors, LLC241,826$2.6M
3Ikarian Capital, LLC238,303$2.5M
4Sofinnova Investments, Inc.222,654$2.4M
5SILVERARC CAPITAL MANAGEMENT, LLC176,057$1.9M
6VANGUARD CAPITAL MANAGEMENT LLC160,473$1.7M
7Pfizer Inc153,354$1.5M
8Opaleye Management Inc.141,181$1.5M
9AWM Investment Company, Inc.117,371$1.2M
10Exome Asset Management LLC115,500$1.2M
11BOOTHBAY FUND MANAGEMENT, LLC69,617$744K
12RENAISSANCE TECHNOLOGIES LLC60,534$647K
13Verdad Advisers, LP42,955$459K
14GEODE CAPITAL MANAGEMENT, LLC31,092$327K
15BlackRock, Inc.27,793$297K